Flu Challenge Study
Trial Summary
Do I have to stop taking my current medications for the trial?
Yes, you must stop taking certain medications that could impact the influenza challenge. This includes prescription or over-the-counter medications like oseltamivir, zanamivir, and others, starting 14 days before and during the quarantine period, unless approved by the investigator.
Will I have to stop taking my current medications?
The trial requires participants to stop using certain medications that could affect the flu challenge or symptoms, such as flu antivirals, aspirin, and some over-the-counter drugs, at least 14 days before and during the quarantine period. It's best to discuss your specific medications with the study investigator to see if they are allowed.
What data supports the idea that Influenza Virus Challenge for Flu is an effective treatment?
The available research does not provide specific data supporting the effectiveness of the Influenza Virus Challenge for Flu as a treatment. The studies mainly discuss the characteristics and spread of different influenza strains, such as H3N2, and the challenges in matching vaccine strains to circulating viruses. There is no direct evidence or comparison to other treatments for the flu in the provided information.12345
What data supports the effectiveness of the treatment Influenza Virus Type A H3N2 Challenge, H3N2 Influenza Challenge Virus, Influenza A(H3N2) Challenge Virus?
What safety data exists for the Influenza A(H3N2) Challenge Virus?
The safety data for the Influenza A(H3N2) Challenge Virus is derived from human challenge studies. These studies have shown that infections with H3N2 viruses generally produce mild symptoms, especially when compared to other influenza subtypes. The studies also indicate that the severity of symptoms is inversely related to the age of the volunteers, with older participants experiencing milder symptoms. Additionally, recombinant H3N2 viruses with genes from H1N1 strains have been shown to produce mild symptoms, suggesting an attenuating effect. Overall, these studies provide evidence of the safety profile of the H3N2 challenge virus in healthy volunteers.14678
Is the Influenza A(H3N2) Challenge Virus safe for humans?
Is the Influenza Virus Type A H3N2 Challenge a promising treatment for flu?
How is the Influenza Virus Type A H3N2 Challenge treatment different from other flu treatments?
The Influenza Virus Type A H3N2 Challenge treatment is unique because it involves intentionally exposing healthy volunteers to a specific strain of the flu virus (H3N2) to study the virus and develop vaccines, rather than treating existing flu infections. This approach helps researchers understand how the virus behaves and how the immune system responds, which is different from typical flu treatments that focus on alleviating symptoms or preventing infection.126910
What is the purpose of this trial?
This study examines how the immune system responds to the flu virus (H3N2) during and after infection and how the flu virus is transmitted in the environment. The study will used a flu virus called the H3N2 influenza challenge virus which was produced specifically for use in clinical research in controlled conditions. The study will also assess the safety of the H3N2 influenza challenge in healthy subjects. Mild to moderate symptoms are expected based on previous studies with this strain of influenza.
Research Team
Nadine Rouphael, MD
Principal Investigator
Emory University
Eligibility Criteria
Healthy adults aged 18-49 who can follow study procedures and are not pregnant, breastfeeding, or planning to become pregnant. They must use birth control if applicable, avoid certain medications before and during the trial, not smoke or use tobacco products, and have no chronic diseases like asthma or heart conditions.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Challenge and Observation
Participants are exposed to the influenza virus and observed for symptoms
Follow-up
Participants are monitored for safety and effectiveness after the challenge
Treatment Details
Interventions
- Influenza Virus Type A H3N2 Challenge
Influenza Virus Type A H3N2 Challenge is already approved in United States, United Kingdom for the following indications:
- Research Use Only - Not for Therapeutic Use
- Research Use Only - Not for Therapeutic Use
Find a Clinic Near You
Who Is Running the Clinical Trial?
Emory University
Lead Sponsor